Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dibotermin alfa
- Development stage
- Phase 4
- Lead developer
- Medtronic
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Implant
01
Overview
Dibotermin alfa is a recombinant human bone morphogenetic protein 2 (rhBMP‑2), produced using Chinese Hamster Ovary (CHO) cells. It is an osteoinductive biologic that binds to receptors on mesenchymal cells, inducing their differentiation into cartilage and bone-forming cells. This promotes new bone formation at the site of implantation, accelerating healing in open tibial shaft fractures and reducing the need for secondary interventions. Dibotermin alfa is primarily used as an adjunct to standard care in certain types of acute tibia fractures and intervertebral disc degeneration. Its mechanism involves stimulating osteogenesis by activating signaling cascades that lead to osteoblast differentiation and enhanced bone repair[1][2][3][4][5][6].
- Brand names
- InductOsINFUSE Bone GraftAmplify rhBMP-2 Matrix
- Other names
- recombinant human bone morphogenetic protein 2bone morphogenetic protein 2
02
Targets
BMPR2 (Bone morphogenetic protein receptor type II)ACVR1 (Activin receptor type I)
Beyond the preview
Go deeper on dibotermin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dibotermin alfa.